ストックスクリーナーアプリを入手
8.59
0.82%
0.07
アフターアワーズ：
8.59
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - Yahoo Finance
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - ad-hoc-news.de
BioCryst Pharmaceuticals (BCRX) Edges Up 0.75% to $8.74 as Shares Approach Key ResistanceOption Breadth - siam.in
Biopharma Stock With Layers of Technical Support in Place - Schaeffer's Investment Research
BCRX Should I Buy - Intellectia AI
BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance
4 Biotech Stocks to Watch as Potential Takeover Targets - Yahoo Finance
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet
BCRX: External innovation and disciplined growth drive rare disease portfolio expansion and profitability - TradingView
BioCryst at Morgan Stanley conference: pivots to external growth - Investing.com
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance UK
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’ - Yahoo Finance
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net
BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
C5 inhibitors disclosed in Biocryst patents - BioWorld News
BioCryst to Present at Upcoming Investor Conference - marketscreener.com
Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan
BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset - Stocktwits
BioCryst Pharmaceuticals Inc. (BCRX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet - Yahoo Finance
BCRXRevenue by Segment - Quiver Quantitative
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
BioCryst gets Japan approval for HAE drug in young children By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals Announces Japan Approval of ORLADEYO for Pediatric HAE Prophylaxis - Quiver Quantitative
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan - The Manila Times
BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now? - sahmcapital.com
NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen - ChartMill
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
BioCryst (BCRX) Quarterly Figures: Reported EPS Tops Expectations in the Latest Reading; Price Reaction: The Share Price Adds 3.81% at the CloseEarnings Growth Analysis - Vinanet
0.18%
0.69%
大文字化:
|
ボリューム (24 時間):